A detailed history of Royal Bank Of Canada transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 87,157 shares of CABA stock, worth $228,351. This represents 0.0% of its overall portfolio holdings.

Number of Shares
87,157
Previous 67,062 29.96%
Holding current value
$228,351
Previous $501,000 17.96%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.94 - $8.24 $79,174 - $165,582
20,095 Added 29.96%
87,157 $411,000
Q2 2024

Aug 14, 2024

SELL
$7.22 - $18.82 $73,521 - $191,644
-10,183 Reduced 13.18%
67,062 $501,000
Q1 2024

Nov 05, 2024

BUY
$16.79 - $25.38 $170,972 - $258,444
10,183 Added 15.18%
77,245 $1.32 Million
Q1 2024

May 15, 2024

SELL
$16.79 - $25.38 $330,947 - $500,265
-19,711 Reduced 20.33%
77,245 $1.32 Million
Q4 2023

Feb 14, 2024

SELL
$12.21 - $23.36 $95,323 - $182,371
-7,807 Reduced 7.45%
96,956 $2.2 Million
Q3 2023

Nov 14, 2023

SELL
$11.84 - $18.65 $130,737 - $205,933
-11,042 Reduced 9.53%
104,763 $1.59 Million
Q2 2023

Aug 14, 2023

BUY
$7.65 - $13.95 $112,508 - $205,162
14,707 Added 14.55%
115,805 $1.5 Million
Q1 2023

May 15, 2023

BUY
$7.08 - $12.62 $714,046 - $1.27 Million
100,854 Added 41333.61%
101,098 $836,000
Q4 2022

Feb 14, 2023

SELL
$0.64 - $9.3 $89 - $1,302
-140 Reduced 36.46%
244 $2,000
Q3 2022

Nov 14, 2022

BUY
$0.63 - $2.05 $241 - $787
384 New
384 $0
Q3 2021

Nov 15, 2021

SELL
$7.0 - $12.5 $10,332 - $18,450
-1,476 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$7.2 - $11.73 $10,627 - $17,313
1,476 New
1,476 $13,000

Others Institutions Holding CABA

About Cabaletta Bio, Inc.


  • Ticker CABA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,014,000
  • Market Cap $76M
  • Description
  • Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...
More about CABA
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.